Dishman Carbogen Amcis Limited (DCAL.NS) Stock Competitors & Peer Comparison
See (DCAL.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DCAL.NS | ₹170.70 | -1.36% | 27.3B | 23.20 | ₹7.51 | N/A |
| BIOCON.NS | ₹416.00 | -1.70% | 575.2B | 130.11 | ₹3.23 | +0.12% |
| BIOCON.BO | ₹415.00 | -1.97% | 575.2B | 134.86 | ₹3.13 | +0.12% |
| ANTHEM.NS | ₹761.40 | -1.88% | 432B | 146.50 | ₹5.25 | N/A |
| ONESOURCE.NS | ₹1,542.00 | -1.65% | 179.3B | -233.43 | -₹6.70 | N/A |
| SYNGENE.NS | ₹437.40 | +0.32% | 178B | 46.33 | ₹9.56 | +0.28% |
| SYNGENE.BO | ₹435.95 | -0.03% | 177.9B | 46.97 | ₹9.43 | +0.28% |
| CONCORDBIO.NS | ₹1,284.80 | -2.50% | 135.1B | 52.22 | ₹24.72 | +0.83% |
| CONCORDBIO.BO | ₹1,296.35 | -1.71% | 134.7B | 51.98 | ₹24.79 | +0.83% |
| BLUEJET.BO | ₹527.35 | +2.45% | 89.7B | 36.23 | ₹14.27 | +0.23% |
Stock Comparison
DCAL.NS vs BIOCON.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, BIOCON.NS has a market cap of 575.2B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while BIOCON.NS trades at ₹416.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas BIOCON.NS's P/E ratio is 130.11. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to BIOCON.NS's ROE of +0.01%. Regarding short-term risk, DCAL.NS is more volatile compared to BIOCON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check BIOCON.NS's competition here
DCAL.NS vs BIOCON.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, BIOCON.BO has a market cap of 575.2B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while BIOCON.BO trades at ₹415.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas BIOCON.BO's P/E ratio is 134.86. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to BIOCON.BO's ROE of +0.01%. Regarding short-term risk, DCAL.NS is more volatile compared to BIOCON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check BIOCON.BO's competition here
DCAL.NS vs ANTHEM.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, ANTHEM.NS has a market cap of 432B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while ANTHEM.NS trades at ₹761.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas ANTHEM.NS's P/E ratio is 146.50. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to ANTHEM.NS's ROE of +0.22%. Regarding short-term risk, DCAL.NS is more volatile compared to ANTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check ANTHEM.NS's competition here
DCAL.NS vs ONESOURCE.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, ONESOURCE.NS has a market cap of 179.3B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while ONESOURCE.NS trades at ₹1,542.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas ONESOURCE.NS's P/E ratio is -233.43. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to ONESOURCE.NS's ROE of -0.01%. Regarding short-term risk, DCAL.NS is more volatile compared to ONESOURCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check ONESOURCE.NS's competition here
DCAL.NS vs SYNGENE.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, SYNGENE.NS has a market cap of 178B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while SYNGENE.NS trades at ₹437.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas SYNGENE.NS's P/E ratio is 46.33. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to SYNGENE.NS's ROE of +0.07%. Regarding short-term risk, DCAL.NS is more volatile compared to SYNGENE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check SYNGENE.NS's competition here
DCAL.NS vs SYNGENE.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, SYNGENE.BO has a market cap of 177.9B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while SYNGENE.BO trades at ₹435.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas SYNGENE.BO's P/E ratio is 46.97. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to SYNGENE.BO's ROE of +0.07%. Regarding short-term risk, DCAL.NS is more volatile compared to SYNGENE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check SYNGENE.BO's competition here
DCAL.NS vs CONCORDBIO.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, CONCORDBIO.NS has a market cap of 135.1B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while CONCORDBIO.NS trades at ₹1,284.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas CONCORDBIO.NS's P/E ratio is 52.22. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to CONCORDBIO.NS's ROE of +0.14%. Regarding short-term risk, DCAL.NS is more volatile compared to CONCORDBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check CONCORDBIO.NS's competition here
DCAL.NS vs CONCORDBIO.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, CONCORDBIO.BO has a market cap of 134.7B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while CONCORDBIO.BO trades at ₹1,296.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas CONCORDBIO.BO's P/E ratio is 51.98. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to CONCORDBIO.BO's ROE of +0.14%. Regarding short-term risk, DCAL.NS is more volatile compared to CONCORDBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check CONCORDBIO.BO's competition here
DCAL.NS vs BLUEJET.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, BLUEJET.BO has a market cap of 89.7B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while BLUEJET.BO trades at ₹527.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas BLUEJET.BO's P/E ratio is 36.23. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to BLUEJET.BO's ROE of +0.20%. Regarding short-term risk, DCAL.NS is less volatile compared to BLUEJET.BO. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check BLUEJET.BO's competition here
DCAL.NS vs BLUEJET.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, BLUEJET.NS has a market cap of 89.6B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while BLUEJET.NS trades at ₹525.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas BLUEJET.NS's P/E ratio is 29.34. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to BLUEJET.NS's ROE of +0.20%. Regarding short-term risk, DCAL.NS is less volatile compared to BLUEJET.NS. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check BLUEJET.NS's competition here
DCAL.NS vs SUPRIYA.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, SUPRIYA.BO has a market cap of 76.9B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while SUPRIYA.BO trades at ₹926.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas SUPRIYA.BO's P/E ratio is 36.74. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to SUPRIYA.BO's ROE of +0.20%. Regarding short-term risk, DCAL.NS is less volatile compared to SUPRIYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check SUPRIYA.BO's competition here
DCAL.NS vs SUPRIYA.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, SUPRIYA.NS has a market cap of 76.7B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while SUPRIYA.NS trades at ₹939.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas SUPRIYA.NS's P/E ratio is 36.70. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to SUPRIYA.NS's ROE of +0.20%. Regarding short-term risk, DCAL.NS is less volatile compared to SUPRIYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check SUPRIYA.NS's competition here
DCAL.NS vs ZOTA.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, ZOTA.NS has a market cap of 42B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while ZOTA.NS trades at ₹1,388.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas ZOTA.NS's P/E ratio is -59.12. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to ZOTA.NS's ROE of -0.21%. Regarding short-term risk, DCAL.NS is more volatile compared to ZOTA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check ZOTA.NS's competition here
DCAL.NS vs PANACEABIO.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, PANACEABIO.BO has a market cap of 34.1B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while PANACEABIO.BO trades at ₹554.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas PANACEABIO.BO's P/E ratio is -300.45. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to PANACEABIO.BO's ROE of -0.01%. Regarding short-term risk, DCAL.NS is less volatile compared to PANACEABIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check PANACEABIO.BO's competition here
DCAL.NS vs PANACEABIO.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, PANACEABIO.NS has a market cap of 34.1B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while PANACEABIO.NS trades at ₹555.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas PANACEABIO.NS's P/E ratio is -300.67. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to PANACEABIO.NS's ROE of -0.01%. Regarding short-term risk, DCAL.NS is less volatile compared to PANACEABIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check PANACEABIO.NS's competition here
DCAL.NS vs DCAL.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, DCAL.BO has a market cap of 27.3B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while DCAL.BO trades at ₹169.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas DCAL.BO's P/E ratio is 27.98. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to DCAL.BO's ROE of +0.02%. Regarding short-term risk, DCAL.NS is more volatile compared to DCAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check DCAL.BO's competition here
DCAL.NS vs TITANBIO.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, TITANBIO.BO has a market cap of 17.1B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while TITANBIO.BO trades at ₹399.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas TITANBIO.BO's P/E ratio is 42.60. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to TITANBIO.BO's ROE of +0.18%. Regarding short-term risk, DCAL.NS is less volatile compared to TITANBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check TITANBIO.BO's competition here
DCAL.NS vs FERMENTA.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, FERMENTA.BO has a market cap of 10.5B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while FERMENTA.BO trades at ₹365.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas FERMENTA.BO's P/E ratio is 11.36. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to FERMENTA.BO's ROE of +0.19%. Regarding short-term risk, DCAL.NS is more volatile compared to FERMENTA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check FERMENTA.BO's competition here
DCAL.NS vs 3BBLACKBIO.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, 3BBLACKBIO.BO has a market cap of 10.1B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while 3BBLACKBIO.BO trades at ₹1,157.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas 3BBLACKBIO.BO's P/E ratio is 46.94. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to 3BBLACKBIO.BO's ROE of +0.20%. Regarding short-term risk, DCAL.NS is more volatile compared to 3BBLACKBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check 3BBLACKBIO.BO's competition here
DCAL.NS vs KILPEST.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, KILPEST.BO has a market cap of 6.3B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while KILPEST.BO trades at ₹808.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas KILPEST.BO's P/E ratio is 18.32. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to KILPEST.BO's ROE of N/A. Regarding short-term risk, DCAL.NS is more volatile compared to KILPEST.BO. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check KILPEST.BO's competition here
DCAL.NS vs SMSLIFE.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, SMSLIFE.BO has a market cap of 4.5B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while SMSLIFE.BO trades at ₹1,400.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas SMSLIFE.BO's P/E ratio is 23.91. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to SMSLIFE.BO's ROE of +0.08%. Regarding short-term risk, DCAL.NS is more volatile compared to SMSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check SMSLIFE.BO's competition here
DCAL.NS vs HALEOSLABS.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, HALEOSLABS.BO has a market cap of 4.5B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while HALEOSLABS.BO trades at ₹1,400.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas HALEOSLABS.BO's P/E ratio is 25.85. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to HALEOSLABS.BO's ROE of +0.09%. Regarding short-term risk, DCAL.NS is more volatile compared to HALEOSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check HALEOSLABS.BO's competition here
DCAL.NS vs TAKE.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, TAKE.BO has a market cap of 4.3B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while TAKE.BO trades at ₹28.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas TAKE.BO's P/E ratio is 40.00. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to TAKE.BO's ROE of +0.44%. Regarding short-term risk, DCAL.NS is less volatile compared to TAKE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check TAKE.BO's competition here
DCAL.NS vs TAKE.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, TAKE.NS has a market cap of 4.2B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while TAKE.NS trades at ₹27.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas TAKE.NS's P/E ratio is 39.47. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to TAKE.NS's ROE of +0.44%. Regarding short-term risk, DCAL.NS is less volatile compared to TAKE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check TAKE.NS's competition here
DCAL.NS vs HALEOSLABS.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, HALEOSLABS.NS has a market cap of 4.1B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while HALEOSLABS.NS trades at ₹1,417.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas HALEOSLABS.NS's P/E ratio is 23.94. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to HALEOSLABS.NS's ROE of +0.09%. Regarding short-term risk, DCAL.NS is less volatile compared to HALEOSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check HALEOSLABS.NS's competition here
DCAL.NS vs SMSLIFE.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, SMSLIFE.NS has a market cap of 3.9B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while SMSLIFE.NS trades at ₹1,299.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas SMSLIFE.NS's P/E ratio is 21.01. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to SMSLIFE.NS's ROE of +0.10%. Regarding short-term risk, DCAL.NS is more volatile compared to SMSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check SMSLIFE.NS's competition here
DCAL.NS vs LYKALABS.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, LYKALABS.BO has a market cap of 2.5B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while LYKALABS.BO trades at ₹69.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas LYKALABS.BO's P/E ratio is -30.58. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to LYKALABS.BO's ROE of -0.10%. Regarding short-term risk, DCAL.NS is less volatile compared to LYKALABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check LYKALABS.BO's competition here
DCAL.NS vs LYKALABS.NS Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, LYKALABS.NS has a market cap of 2.5B. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while LYKALABS.NS trades at ₹71.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas LYKALABS.NS's P/E ratio is -24.98. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to LYKALABS.NS's ROE of -0.10%. Regarding short-term risk, DCAL.NS is less volatile compared to LYKALABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check LYKALABS.NS's competition here
DCAL.NS vs ALFAVIO.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, ALFAVIO.BO has a market cap of 274.3M. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while ALFAVIO.BO trades at ₹9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas ALFAVIO.BO's P/E ratio is -47.83. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to ALFAVIO.BO's ROE of +0.00%. Regarding short-term risk, DCAL.NS is more volatile compared to ALFAVIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check ALFAVIO.BO's competition here
DCAL.NS vs TRABI.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, TRABI.BO has a market cap of 229.6M. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while TRABI.BO trades at ₹3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas TRABI.BO's P/E ratio is -35.35. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to TRABI.BO's ROE of -0.18%. Regarding short-term risk, DCAL.NS is less volatile compared to TRABI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check TRABI.BO's competition here
DCAL.NS vs VANTABIO.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, VANTABIO.BO has a market cap of 180.3M. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while VANTABIO.BO trades at ₹24.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas VANTABIO.BO's P/E ratio is 169.00. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to VANTABIO.BO's ROE of -0.17%. Regarding short-term risk, DCAL.NS is more volatile compared to VANTABIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for DCAL.NS.Check VANTABIO.BO's competition here
DCAL.NS vs SAMSRITA.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, SAMSRITA.BO has a market cap of 177.7M. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while SAMSRITA.BO trades at ₹12.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas SAMSRITA.BO's P/E ratio is -8.89. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to SAMSRITA.BO's ROE of -0.64%. Regarding short-term risk, DCAL.NS is less volatile compared to SAMSRITA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check SAMSRITA.BO's competition here
DCAL.NS vs STARSOURCE.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, STARSOURCE.BO has a market cap of 138.2M. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while STARSOURCE.BO trades at ₹90.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas STARSOURCE.BO's P/E ratio is -1.17. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to STARSOURCE.BO's ROE of -0.93%. Regarding short-term risk, DCAL.NS is less volatile compared to STARSOURCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check STARSOURCE.BO's competition here
DCAL.NS vs GVBL.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, GVBL.BO has a market cap of 107.2M. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while GVBL.BO trades at ₹33.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas GVBL.BO's P/E ratio is 351.10. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to GVBL.BO's ROE of -0.01%. Regarding short-term risk, DCAL.NS is less volatile compared to GVBL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check GVBL.BO's competition here
DCAL.NS vs SERVOTEACH.BO Comparison June 2026
DCAL.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCAL.NS stands at 27.3B. In comparison, SERVOTEACH.BO has a market cap of 0. Regarding current trading prices, DCAL.NS is priced at ₹170.70, while SERVOTEACH.BO trades at ₹20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCAL.NS currently has a P/E ratio of 23.20, whereas SERVOTEACH.BO's P/E ratio is N/A. In terms of profitability, DCAL.NS's ROE is +0.02%, compared to SERVOTEACH.BO's ROE of +0.00%. Regarding short-term risk, DCAL.NS is less volatile compared to SERVOTEACH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for DCAL.NS.Check SERVOTEACH.BO's competition here